Although Atripla is currently not available in generic form, several drug companies could begin manufacturing generic Atripla products as soon as the patents for the medication expire in 2018. Other patents for specific uses or lawsuits could delay the medication's availability. Until generic Atripla is available, if you need help affording HIV medications, talk with your healthcare provider.
Atripla™ (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) is a prescription HIV and AIDS medication. It contains three different HIV medications:
Atripla is approved for use alone or in combination with other HIV medications.
The medication is made jointly by Bristol-Myers Squibb and Gilead Sciences, Inc. It is currently under the protection of patents that prevent any generic Atripla from being manufactured in the United States.
The first patents for the three active ingredients in Atripla will all have expired by January 2018. This is the earliest possible date that a generic version of the drug could become available. However, other circumstances could come up to extend the exclusivity period beyond 2018. This could include such things as other patents for specific Atripla uses or lawsuits. Once the patents expire, several companies will likely begin manufacturing a generic Atripla drug.
HIV medications can be expensive. While most insurance companies cover HIV medications, not everyone has prescription insurance coverage. If you have trouble affording your HIV medications, please speak with your healthcare provider. Many different programs are available to help provide HIV medications to qualified people at little or no cost. These programs may include government programs (such as Medicaid) or programs from the drug manufacturers.